Literature DB >> 35373137

Proactive High-Dose IV Iron Is Preferred Therapy in ESKD Patients: PRO.

Daniel W Coyne1.   

Abstract

Entities:  

Keywords:  debate; dialysis; ferryl iron; hemodialysis; iron; mortality

Mesh：

Substances：

Year:  2021        PMID： 35373137      PMCID： PMC8967649          DOI： 10.34067/KID.0002442021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  12 in total

1.  The Value of Intravenous Iron: Beyond the Cave of Speculation.

Authors:  Daniel W Coyne; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2020-04-06       Impact factor: 10.121

2.  Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.

Authors:  Daniel W Coyne; Toros Kapoian; Wadi Suki; Ajay K Singh; John E Moran; Naomi V Dahl; Adel R Rizkala
Journal:  J Am Soc Nephrol       Date:  2007-01-31       Impact factor: 10.121

3.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

4.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Authors:  A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

Review 5.  Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.

Authors:  Stefan D Anker; Bridget-Anne Kirwan; Dirk J van Veldhuisen; Gerasimos Filippatos; Josep Comin-Colet; Frank Ruschitzka; Thomas F Lüscher; Gregory P Arutyunov; Michael Motro; Claudio Mori; Bernard Roubert; Stuart J Pocock; Piotr Ponikowski
Journal:  Eur J Heart Fail       Date:  2017-04-24       Impact factor: 15.534

6.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

7.  Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients.

Authors:  Lillian A Rocha; Daniela V Barreto; Fellype C Barreto; Cristiane B Dias; Rosa Moysés; Maria Regina R Silva; Luiz A R Moura; Sérgio A Draibe; Vanda Jorgetti; Aluízio B Carvalho; Maria Eugênia F Canziani
Journal:  Clin J Am Soc Nephrol       Date:  2008-10-08       Impact factor: 8.237

8.  Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

Authors:  Iain C Macdougall; Claire White; Stefan D Anker; Sunil Bhandari; Kenneth Farrington; Philip A Kalra; John J V McMurray; Heather Murray; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford
Journal:  N Engl J Med       Date:  2018-10-26       Impact factor: 91.245

9.  The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.

Authors:  Daniel W Coyne
Journal:  Kidney Int       Date:  2012-03-21       Impact factor: 10.612

Review 10.  Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations.

Authors:  Guy Rostoker; Nosratola D Vaziri
Journal:  Heliyon       Date:  2019-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.